Biotechnology companies in Italy. BioinItaly Report 2018
The 2018 report “BioInItaly Report 2018", created by Assobiotec, made up of Federchimica, and ENEA, both Airi members, notes that the Italian biotechnology industry is experiencing a phase of consolidation on the most solid and competitive corporate realities, confirming itself as highly research-intensive. moreThe photograph of biotechnology in Italy, with 571 companies, confirms the primacy of companies operating in biotechnologies applied to human health, which represent over half of Italian biotech companies (52%). Below we note the presence of companies focused on industry and the environment which are 28% of the total. A portion is reserved for companies active in Genomics; Proteomics and Enabling Technologies and finally the biotechnology sector applied to agriculture and livestock.
Of the total companies dedicated to biotech R&D, the share of micro or small ones is close to 90%, although in the last four years there has been a reduction in the share of micro companies in the total due to both the consolidation of the sector and the effects produced by a prolonged economic situation.
Companies active in the healthcare sector generate three-quarters of total biotech turnover. It is precisely in the health area that companies with foreign capital generate the majority of their turnover, while among those with Italian capital it is the sector dedicated to industry and the environment that contributes significantly to the total biotech turnover.
Biotech companies are characterized by a high projection on foreign markets (38%) more than one and a half times compared to the manufacturing sector (23%) and more than seven times that relating to the Italian industry as a whole (5%). The distribution of biotech exports is polarized at a territorial level in four regions, accounting for more than 90% of the total: Lombardy, Piedmont, Tuscany and Lazio. Investments in biotech R&D represent 35% of overall investments in R&D for the total companies analyzed, this figure rises to 90% for companies dedicated to biotech R&D with Italian capital. The amount of spending on biotech R&D stands at around 764 million euros, an increase of 22% compared to 2014. 34% of total biotech investments are intended to finance research activities carried out in outsourcing (extra-muros biotech investments), while 67% of research activities are carried out internally by companies (intra-muros biotech investments).
From the report, the data of which will be included in the statistics on the biotechnology industry managed by the OECD, on the one hand we can see a growing attention on the part of policy makers towards the sector and more generally towards Research and Innovation. This was possible through some initiatives, which resulted in the National Enterprise 4.0 plan in 2017, such as, for example, the recognition of innovative Start Ups and SMEs, the adoption of a preferential tax regime on intellectual property income (Patent Box), the tax credit for investments in R&D, which to date is the most important tax benefit for businesses. On the other hand, however, it is necessary to support the sector in a structured way and with a long-term strategic approach in order to compete internationally in biotechnology.
You may also be interested in the following content:
-
brand_awareness Priority Technologies: a unique foresight at the national level
-
brand_awareness Extra-mural R&D in 2014 grows to 2.4 billion euros
-
brand_awareness Three calls for research projects in Argentina